Literature DB >> 23603256

MicroRNA-19a/b regulates multidrug resistance in human gastric cancer cells by targeting PTEN.

Fang Wang1, Ting Li, Bin Zhang, Hong Li, Qiong Wu, Li Yang, Yongzhan Nie, Kaichun Wu, Yongquan Shi, Daiming Fan.   

Abstract

Multidrug resistance (MDR) is the major cause of failure of gastric cancer chemotherapy. Members of the miR-17-92 cluster, including miR-19a/b, are considered oncomiRs and influence multiple aspects of the malignant phenotype of gastric cancer. However, the role of miR-19a/b in MDR in gastric cancer and its underlying mechanism remain unclear. In this study, we found that miR-19a/b were upregulated in MDR cell lines. Our results also showed that miR-19a/b upregulation decreased the sensitivity of gastric cancer cells to anticancer drugs. We further confirmed that miR-19a/b accelerated the ADR efflux of gastric cancer cells by increasing the levels of mdr1 and P-gp and that miR-19a/b suppressed drug-induced apoptosis by regulating Bcl-2 and Bax. Finally, we verified that PTEN, an inhibitor of AKT phosphorylation, is the functional target of miR-19a/b. Overall, these findings demonstrated that miR-19a/b promote MDR in gastric cancer cells by targeting PTEN.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23603256     DOI: 10.1016/j.bbrc.2013.04.010

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  70 in total

Review 1.  MicroRNA Pharmacoepigenetics: Posttranscriptional Regulation Mechanisms behind Variable Drug Disposition and Strategy to Develop More Effective Therapy.

Authors:  Ai-Ming Yu; Ye Tian; Mei-Juan Tu; Pui Yan Ho; Joseph L Jilek
Journal:  Drug Metab Dispos       Date:  2015-11-13       Impact factor: 3.922

2.  Quantitatively controlling expression of miR-17~92 determines colon tumor progression in a mouse tumor model.

Authors:  Hong Jiang; Ping Wang; Qilong Wang; Baomei Wang; Jingyao Mu; Xiaoying Zhuang; Lifeng Zhang; Jun Yan; Donald Miller; Huang-Ge Zhang
Journal:  Am J Pathol       Date:  2014-03-27       Impact factor: 4.307

3.  MicroRNA-21 promotes phosphatase gene and protein kinase B/phosphatidylinositol 3-kinase expression in colorectal cancer.

Authors:  Wei-Zhong Sheng; Yu-Sheng Chen; Chuan-Tao Tu; Juan He; Bo Zhang; Wei-Dong Gao
Journal:  World J Gastroenterol       Date:  2016-06-28       Impact factor: 5.742

4.  MiR-19a promotes epithelial-mesenchymal transition through PI3K/AKT pathway in gastric cancer.

Authors:  Wei-Dong Lu; Yun Zuo; Zhen Xu; Min Zhang
Journal:  World J Gastroenterol       Date:  2015-04-21       Impact factor: 5.742

5.  MicroRNA-429 inhibits gastric cancer migration and invasion through the downregulation of specificity protein 1.

Authors:  Jingbin Ni; Yisha Yang; Di Liu; Hui Sun; Shimao Jin; Jingying Li
Journal:  Oncol Lett       Date:  2017-03-17       Impact factor: 2.967

6.  MicroRNA-19b promotes the migration and invasion of ovarian cancer cells by inhibiting the PTEN/AKT signaling pathway.

Authors:  Dan-Tong Liu; Hai-Rong Yao; Yan-Ying Li; Yang-Yang Song; Meng-Ya Su
Journal:  Oncol Lett       Date:  2018-05-10       Impact factor: 2.967

7.  MicroRNA-451 regulates chemoresistance in renal cell carcinoma by targeting ATF-2 gene.

Authors:  Xiang Sun; Longhua Lou; Kezhao Zhong; Lijuan Wan
Journal:  Exp Biol Med (Maywood)       Date:  2017-04-21

8.  Downregulation of microRNA-193-3p inhibits tumor proliferation migration and chemoresistance in human gastric cancer by regulating PTEN gene.

Authors:  Bin Jian; Zhongfu Li; Dachun Xiao; Gan He; Lian Bai; Qiang Yang
Journal:  Tumour Biol       Date:  2016-01-11

Review 9.  Molecular pathways involved in microRNA-mediated regulation of multidrug resistance.

Authors:  Rongrong Liao; Yuexia Lin; Lihui Zhu
Journal:  Mol Biol Rep       Date:  2018-09-07       Impact factor: 2.316

Review 10.  How to stomach an epigenetic insult: the gastric cancer epigenome.

Authors:  Nisha Padmanabhan; Toshikazu Ushijima; Patrick Tan
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-05-17       Impact factor: 46.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.